Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Xenotransplantation ; 23(3): 222-236, 2016 05.
Article in English | MEDLINE | ID: mdl-27188532

ABSTRACT

BACKGROUND: Here, we ask whether platelet GPIb and GPIIb/IIIa receptors modulate platelet sequestration and activation during GalTKO.hCD46 pig lung xenograft perfusion. METHODS: GalTKO.hCD46 transgenic pig lungs were perfused with heparinized fresh human blood. Results from perfusions in which αGPIb Fab (6B4, 10 mg/l blood, n = 6), αGPIIb/IIIa Fab (ReoPro, 3.5 mg/l blood, n = 6), or both drugs (n = 4) were administered to the perfusate were compared to two additional groups in which the donor pig received 1-desamino-8-d-arginine vasopressin (DDAVP), 3 µg/kg (to pre-deplete von Willebrand Factor (pVWF), the main GPIb ligand), with or without αGPIb (n = 6 each). RESULTS: Platelet sequestration was significantly delayed in αGPIb, αGPIb+DDAVP, and αGPIb+αGPIIb/IIIa groups. Median lung "survival" was significantly longer (>240 vs. 162 min reference, p = 0.016), and platelet activation (as CD62P and ßTG) were significantly inhibited, when pigs were pre-treated with DDAVP, with or without αGPIb Fab treatment. Pulmonary vascular resistance rise was not significantly attenuated in any group, and was associated with residual thromboxane and histamine elaboration. CONCLUSIONS: The GPIb-VWF and GPIIb/IIIa axes play important roles in platelet sequestration and coagulation cascade activation during GalTKO.hCD46 lung xenograft injury. GPIb blockade significantly reduces platelet activation and delays platelet sequestration in this xenolung rejection model, an effect amplified by adding αGPIIb/IIIa blockade or depletion of VWF from pig lung.


Subject(s)
Blood Platelets/cytology , Lung/metabolism , Platelet Aggregation/genetics , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Platelet Glycoprotein GPIb-IX Complex/metabolism , von Willebrand Factor/metabolism , Animals , Animals, Genetically Modified , Graft Survival/immunology , Heterografts/immunology , Humans , Lung/immunology , Lung Transplantation/methods , Platelet Activation/physiology , Platelet Aggregation/immunology , Platelet Glycoprotein GPIb-IX Complex/genetics , Swine , Thrombocytopenia/etiology , Transplantation, Heterologous/methods , von Willebrand Factor/genetics
2.
Am J Transplant ; 14(5): 1084-95, 2014 May.
Article in English | MEDLINE | ID: mdl-24698431

ABSTRACT

Evaluation of lungs from GalTKO.hCD46 pigs, genetically modified to lack the galactose-α(1,3)-galactose epitope (GalTKO) and to express human CD46, a complement regulatory protein, has not previously been described. Physiologic, hematologic and biochemical parameters during perfusion with heparinized fresh human blood were measured for 33 GalTKO.hCD46, GalTKO (n = 16), and WT pig lungs (n = 16), and 12 pig lungs perfused with autologous pig blood. Median GalTKO.hCD46 lung survival was 171 min compared to 120 for GalTKO (p = 0.27) and 10 for WT lungs (p < 0.001). Complement activation, platelet activation and histamine elaboration were significantly reduced during the first 2 h of perfusion in GalTKO.hCD46 lungs compared to GalTKO (ΔC3a at 120' 812 ± 230 vs. 1412 ± 1047, p = 0.02; ΔCD62P at 120' 9.8 ± 7.2 vs. 25.4 ± 18.2, p < 0.01; Δhistamine at 60' 97 ± 62 vs. 189 ± 194, p = 0.03). We conclude that, in addition to significant down-modulation of complement activation, hCD46 expression in GalTKO lungs diminished platelet and coagulation cascade activation, neutrophil sequestration and histamine release. Because GalTKO.hCD46 lung failure kinetics correlated directly with platelet and neutrophil sequestration, coagulation cascade activation and a rise in histamine levels within the first hour of perfusion, further progress will likely depend upon improved control of these pathways, by rationally targeted additional modifications to pigs and pharmacologic interventions.


Subject(s)
CD55 Antigens/genetics , Galactosyltransferases/physiology , Graft Survival/physiology , Inflammation/pathology , Lung Injury/immunology , Lung Transplantation , Animals , Animals, Genetically Modified , Blood Coagulation/immunology , Complement Activation/immunology , Epitopes/immunology , Histamine/metabolism , Humans , Immunoenzyme Techniques , Inflammation/immunology , Inflammation/metabolism , Lung Injury/pathology , Lung Injury/surgery , Neutrophils/metabolism , Swine , Swine, Miniature , Transplantation, Heterologous
3.
FASEB J ; 8(6): 448-51, 1994 Apr 01.
Article in English | MEDLINE | ID: mdl-7909525

ABSTRACT

HIV-infected individuals and SIV-infected rhesus macaques have, on the average, decreased plasma cysteine and cystine concentrations and decreased intracellular glutathione levels. We show that the cysteine supply and the intracellular glutathione levels have a strong influence on the T cell system. A study of healthy human subjects revealed that persons with intracellular glutathione levels of 20-30 nmol/mg protein had significantly higher numbers of CD4+ T cells than persons with either lower or higher glutathione levels. Persons who moved during a 4-week observation period from the optimal to the suboptimal range (10-20 nmol/mg) experienced, on the average, a 30% decrease in CD4+ T cell numbers. This decrease was prevented by treatment with N-acetyl-cysteine (NAC). NAC caused this relative increase of CD4+ T cell numbers in spite of decreasing glutathione levels and not by increasing the glutathione level. Our studies suggest that the immune system may be exquisitely sensitive not only against a cysteine and glutathione deficiency but also against an excess of cysteine.


Subject(s)
Acetylcysteine/pharmacology , CD4-Positive T-Lymphocytes/drug effects , CD8 Antigens/analysis , Glutathione/analysis , T-Lymphocytes/drug effects , Acetylcysteine/administration & dosage , Administration, Oral , Adult , Double-Blind Method , Humans , Leukocyte Count/drug effects , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL